Paul K Drain1,2,3, Ashley R Bardon4,5, Jane M Simoni4,6,7, Tim R Cressey8,9,10, Pete Anderson11, Derin Sevenler12, Ayokunle O Olanrewaju13, Monica Gandhi14, Connie Celum4,15. 1. Department of Global Health, Schools of Medicine and Public Health, University of Washington, 325 Ninth Ave, UW Box 359927, Seattle, WA, 98104-2420, USA. pkdrain@uw.edu. 2. Department of Medicine, School of Medicine, University of Washington, 325 Ninth Ave, UW Box 359927, Seattle, WA, 98104-2420, USA. pkdrain@uw.edu. 3. Department of Epidemiology, School of Public Health, University of Washington, 325 Ninth Ave, UW Box 359927, Seattle, WA, 98104-2420, USA. pkdrain@uw.edu. 4. Department of Global Health, Schools of Medicine and Public Health, University of Washington, 325 Ninth Ave, UW Box 359927, Seattle, WA, 98104-2420, USA. 5. Department of Epidemiology, School of Public Health, University of Washington, 325 Ninth Ave, UW Box 359927, Seattle, WA, 98104-2420, USA. 6. Department of Psychology, University of Washington, Seattle, USA. 7. Department of Gender, Women, and Sexuality Studies, University of Washington, Seattle, USA. 8. PHPT/IRD 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. 9. Harvard T.H. Chan School of Public Health, Harvard University, Boston, USA. 10. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. 11. Department of Pharmaceutical Sciences, University of Colorado, Aurora, Aurora, CO, USA. 12. Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA. 13. Department of Mechanical Engineering, University of Washington, Seattle, USA. 14. Department of Medicine, University of California, San Francisco, San Francisco, USA. 15. Department of Medicine, School of Medicine, University of Washington, 325 Ninth Ave, UW Box 359927, Seattle, WA, 98104-2420, USA.
Abstract
PURPOSE OF REVIEW: In this report, we review the need for point-of-care (POC) or near real-time testing for antiretrovirals, progress in the field, evidence for guiding implementation of these tests globally, and future directions in objective antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) adherence monitoring. RECENT FINDINGS: Two cornerstones to end the HIV/AIDS pandemic are ART, which provides individual clinical benefits and eliminates forward transmission, and PrEP, which prevents HIV acquisition with high effectiveness. Maximizing the individual and public health benefits of these powerful biomedical tools requires high and sustained antiretroviral adherence. Routine monitoring of medication adherence in individuals receiving ART and PrEP may be an important component in interpreting outcomes and supporting optimal adherence. Existing practices and subjective metrics for adherence monitoring are often inaccurate or unreliable and, therefore, are generally ineffective for improving adherence. Laboratory measures of antiretroviral concentrations using liquid chromatography tandem mass spectrometry have been utilized in research settings to assess medication adherence, although these are too costly and resource-intensive for routine use. Newer, less costly technologies such as antibody-based methods can provide objective drug-level measurement and may allow for POC or near-patient adherence monitoring in clinical settings. When coupled with timely and targeted counseling, POC drug-level measures can support adherence clinic-based interventions to ART or PrEP in near real time.
PURPOSE OF REVIEW: In this report, we review the need for point-of-care (POC) or near real-time testing for antiretrovirals, progress in the field, evidence for guiding implementation of these tests globally, and future directions in objective antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) adherence monitoring. RECENT FINDINGS: Two cornerstones to end the HIV/AIDS pandemic are ART, which provides individual clinical benefits and eliminates forward transmission, and PrEP, which prevents HIV acquisition with high effectiveness. Maximizing the individual and public health benefits of these powerful biomedical tools requires high and sustained antiretroviral adherence. Routine monitoring of medication adherence in individuals receiving ART and PrEP may be an important component in interpreting outcomes and supporting optimal adherence. Existing practices and subjective metrics for adherence monitoring are often inaccurate or unreliable and, therefore, are generally ineffective for improving adherence. Laboratory measures of antiretroviral concentrations using liquid chromatography tandem mass spectrometry have been utilized in research settings to assess medication adherence, although these are too costly and resource-intensive for routine use. Newer, less costly technologies such as antibody-based methods can provide objective drug-level measurement and may allow for POC or near-patient adherence monitoring in clinical settings. When coupled with timely and targeted counseling, POC drug-level measures can support adherence clinic-based interventions to ART or PrEP in near real time.
Authors: H C Koenig; K Mounzer; G W Daughtridge; C E Sloan; L Lalley-Chareczko; G S Moorthy; S C Conyngham; A F Zuppa; L J Montaner; P Tebas Journal: HIV Med Date: 2017-04-26 Impact factor: 3.180
Authors: Jessica E Haberer; Gregory K Robbins; Michele Ybarra; Alexandra Monk; Kathleen Ragland; Sheri D Weiser; Mallory O Johnson; David R Bangsberg Journal: AIDS Behav Date: 2012-02
Authors: William M Gilliland; Heather M A Prince; Amanda Poliseno; Angela D M Kashuba; Elias P Rosen Journal: Anal Chem Date: 2019-08-06 Impact factor: 6.986
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Leslie Cottle; Xinyi C Zhang; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Sharlaa Faesen; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David D Celentano; Max Essex; Sarah E Hudelson; Andrew D Redd; Thomas R Fleming Journal: N Engl J Med Date: 2016-07-18 Impact factor: 91.245
Authors: Monica Gandhi; Guohong Wang; Roger King; Warren C Rodrigues; Michael Vincent; David V Glidden; Tim R Cressey; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Oraphan Siriprakaisil; Virat Klinbuayaem; Nelly R Mugo; Kenneth Ngure; Paul K Drain; Jared M Baeten Journal: AIDS Date: 2020-02-01 Impact factor: 4.632
Authors: Deborah Donnell; Jared M Baeten; Namandjé N Bumpus; Justin Brantley; David R Bangsberg; Jessica E Haberer; Andrew Mujugira; Nelly Mugo; Patrick Ndase; Craig Hendrix; Connie Celum Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731
Authors: Marie A Brault; Donna Spiegelman; James Hargreaves; Denis Nash; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2019-12-01 Impact factor: 3.731
Authors: Lila Starbuck; Sarit A Golub; Augustus Klein; Alexander B Harris; Amiyah Guerra; Christopher Rincon; Asa E Radix Journal: J Acquir Immune Defic Syndr Date: 2022-05-01 Impact factor: 3.771
Authors: Ayokunle O Olanrewaju; Benjamin P Sullivan; Ashley R Bardon; Tiffany J Lo; Tim R Cressey; Jonathan D Posner; Paul K Drain Journal: Virol J Date: 2021-04-15 Impact factor: 5.913
Authors: Xin Niu; Rachel W Kubiak; Oraphan Siriprakaisil; Virat Klinbuyaem; Pra Ornsuda Sukrakanchana; Ratchada Cressey; Hideaki Okochi; Monica Gandhi; Tim R Cressey; Paul K Drain Journal: Open Forum Infect Dis Date: 2022-08-10 Impact factor: 4.423